. 2018 Jul 30;2018:2124390. doi: 10.1155/2018/2124390

Table 2.

Plasma levels of examined parameters and CA 15-3 in patients with breast cancer and in control groups.

Groups tested	CCL2	CCR2	CA 15-3
Groups tested	(pg/mL)	(ng/mL)	(U/mL)
Breast cancer (median, range)

Stage I	192.81 (36.68-438.58)^b/f	1.34 (0.11-8.17)^a/f	17.15 (6.20-50.30)^a/b/f
Stage II	227.22 (1.45-1631.48)^b/f	0.93 (0.05-6.16)^a/b/f	17.60 (4.40-48.10)^a/b/f
Stage III and IV	398.55 (99.12-592.30)^a/b/c/d/f	0.92 (0.34-3.81)^a/b/f	27.75 (8.90-250.00)^a/b/c/d/f
Total group	228.34 (1.45-1631.48)^a/b/f	0.96 (0.05-8.17)^a/f	19.20 (4.40-250.00)^a/b/f

Control groups (median, range)

Benign breast tumor	118.64 (37.37-489.88)^e	1.82 (0.05-7.67)^e	14.00 (5.20-20.70)
Healthy women	155.17 (70.58-440.06)	3.45 (0.84-22.60)	13.40 (6.30-28.40)
Total control group	130.64 (37.37-489.88)	2.30 (0.05-22.60)	13.60 (5.20-28.40)

Notes: ^astatistically significant when patients with BC compared with healthy women.^bStatistically significant when patients with BC compared with benign breast tumor group. ^cStatistically significant when patients with BC stages III and IV compared with patients with BC stage I. ^dStatistically significant when patients with BC stages III and IV compared with patients with BC stage II. ^eStatistically significant when patients with benign breast tumor compared with healthy women. ^fStatistically significant when patients with BC compared with total control group.